Patrick Flume to Adult
This is a "connection" page, showing publications Patrick Flume has written about Adult.
Connection Strength
1.133
-
Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection. Respir Med. 2023 01; 206:107069.
Score: 0.058
-
Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 2022 01; 21(1):96-103.
Score: 0.053
-
Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study. J Cyst Fibros. 2021 11; 20(6):1003-1009.
Score: 0.051
-
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746.
Score: 0.051
-
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. J Cyst Fibros. 2021 03; 20(2):288-294.
Score: 0.051
-
Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis. J Genet Couns. 2018 09; 27(5):1049-1054.
Score: 0.042
-
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815.
Score: 0.037
-
Adults with cystic fibrosis in Portugal: A first step towards improvement. Rev Port Pneumol (2006). 2016 May-Jun; 22(3):139-40.
Score: 0.037
-
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst Rev. 2015 Jul 30; (7):CD009730.
Score: 0.035
-
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14.
Score: 0.034
-
Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. J Cyst Fibros. 2013 Jul; 12(4):403-6.
Score: 0.029
-
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-724.
Score: 0.028
-
Update in cystic fibrosis 2009. Am J Respir Crit Care Med. 2010 Mar 15; 181(6):539-44.
Score: 0.024
-
Treatment of pulmonary exacerbations in adult cystic fibrosis patients: a review. Hosp Pract (1995). 2010 Feb; 38(1):26-34.
Score: 0.024
-
Smoothing the transition from pediatric to adult care: lessons learned. Curr Opin Pulm Med. 2009 Nov; 15(6):611-4.
Score: 0.023
-
Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Sep; 8(5):321-5.
Score: 0.023
-
Making the diagnosis of cystic fibrosis. Am J Med Sci. 2008 Jan; 335(1):51-4.
Score: 0.021
-
Pneumothorax in cystic fibrosis. Chest. 2005 Aug; 128(2):720-8.
Score: 0.017
-
Massive hemoptysis in cystic fibrosis. Chest. 2005 Aug; 128(2):729-38.
Score: 0.017
-
An unusual presentation of cystic fibrosis in an adult. Am J Kidney Dis. 2005 Mar; 45(3):e41-4.
Score: 0.017
-
Testing two different doses of tiotropium Respimat? in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014; 9(9):e106195.
Score: 0.016
-
Transition programs in cystic fibrosis centers: perceptions of team members. Pediatr Pulmonol. 2004 Jan; 37(1):4-7.
Score: 0.016
-
Telehealth and CFTR modulators: Accelerating innovative models of cystic fibrosis care. J Cyst Fibros. 2023 Jan; 22(1):9-16.
Score: 0.014
-
Abdominal Surgical Procedures in Adult Patients With Cystic Fibrosis: What Are the Risks? Dis Colon Rectum. 2022 08 01; 65(8):e805-e815.
Score: 0.014
-
A "story" of a woman with cystic fibrosis. Chest. 2002 May; 121(5):1704-7.
Score: 0.014
-
Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion. BMC Infect Dis. 2022 Mar 12; 22(1):246.
Score: 0.014
-
Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition. Nutr Clin Pract. 2022 Apr; 37(2):344-350.
Score: 0.014
-
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med. 2021 12 01; 204(11):1295-1305.
Score: 0.014
-
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation. J Cyst Fibros. 2022 07; 21(4):574-580.
Score: 0.014
-
Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Sci Rep. 2021 07 09; 11(1):14232.
Score: 0.013
-
Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Ann Am Thorac Soc. 2021 07; 18(7):1147-1157.
Score: 0.013
-
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Chest. 2021 09; 160(3):831-842.
Score: 0.013
-
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. J Cyst Fibros. 2021 01; 20(1):78-85.
Score: 0.012
-
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. J Cyst Fibros. 2021 01; 20(1):36-38.
Score: 0.012
-
Complications of cystic fibrosis in adults. J S C Med Assoc. 2000 Mar; 96(3):112-7.
Score: 0.012
-
Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2020 05; 19(3):370-375.
Score: 0.012
-
Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414.
Score: 0.011
-
ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 03; 17(2):153-178.
Score: 0.010
-
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 01; 17(1):83-88.
Score: 0.010
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep; 16(5):600-606.
Score: 0.010
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599.
Score: 0.010
-
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. J Cyst Fibros. 2017 09; 16(5):607-615.
Score: 0.010
-
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379.
Score: 0.010
-
Relief of the 'air hunger' of breathholding. A role for pulmonary stretch receptors. Respir Physiol. 1996 Mar; 103(3):221-32.
Score: 0.009
-
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros. 2016 09; 15(5):634-40.
Score: 0.009
-
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502.
Score: 0.009
-
Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33.
Score: 0.009
-
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul; 3(7):524-33.
Score: 0.009
-
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 07 16; 373(3):220-31.
Score: 0.009
-
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep; 2(9):738-49.
Score: 0.008
-
Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7.
Score: 0.008
-
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014 May; 13 Suppl 1:S23-42.
Score: 0.008
-
Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant. 1994 Jan-Feb; 13(1 Pt 1):15-21; discussion 22-3.
Score: 0.008
-
The Fowler breathholding study revisited: continuous rating of respiratory sensation. Respir Physiol. 1994 Jan; 95(1):53-66.
Score: 0.008
-
Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013 Jul; 12(4):367-76.
Score: 0.007
-
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52.
Score: 0.007
-
Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011 Jun; 55(6):2636-40.
Score: 0.006
-
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6.
Score: 0.006
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61.
Score: 0.006
-
Cost-effective airway cultures in the cystic fibrosis patient. Am J Otolaryngol. 2009 May-Jun; 30(3):150-2.
Score: 0.005
-
The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol. 2007 Jan-Feb; 21(1):122-7.
Score: 0.005
-
Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis. Pediatr Pulmonol. 2006 Jul; 41(7):683-7.
Score: 0.005
-
Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen. J Mol Diagn. 2006 Feb; 8(1):137-40.
Score: 0.005
-
Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet. 2005 Nov 15; 14(22):3493-8.
Score: 0.004
-
Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care. 2004 Dec; 49(12):1504-8.
Score: 0.004
-
Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004 Jan; 48(1):281-4.
Score: 0.004
-
Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Sep; 30(9):2064-9.
Score: 0.004
-
Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002 Mar; 73(3):922-6.
Score: 0.003
-
Psychological functioning of adults with cystic fibrosis. Chest. 2001 Apr; 119(4):1079-84.
Score: 0.003
-
A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy. 1999 May; 19(5):620-6.
Score: 0.003
-
The MUSC lung transplantation program: the first year's experience. J S C Med Assoc. 1995 May; 91(5):223-7.
Score: 0.002